Dr. Aaron C. Ermel, MD
Infectious Disease (Infectious Disease Physician)
- Medicare participating
At a glance
- Medical school
- Indiana University School of Medicine (2006)
- Years since graduation
- 20
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 68
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Medical school: Indiana University School of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Infectious Disease Physician primary
IN license 01066812A
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Indiana University Health Indianapolis, IN
Medical groups
- Iu Health Medical Group LLC (4,462 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 68
- Services billed
- 141
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 87 | 39 |
| Established patient office or other outpatient visit, 20-29 minutes | 44 | 25 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 39 | 18 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 20 | 20 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 13 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Biktarvy (bictegrav/emtricit/tenofov ala) | 178 |
| Triumeq (abacavir/dolutegravir/lamivudi) | 61 |
| Tivicay (dolutegravir sodium) | 60 |
| Amikacin Sulfate | 38 |
| Descovy (emtricitabine/tenofov alafenam) | 37 |
| Imipenem-Cilastatin Sodium (imipenem/cilastatin sodium) | 29 |
| Symtuza (darunavir/cob/emtri/tenof alaf) | 25 |
| Odefsey (emtricitab/rilpiviri/tenof ala) | 24 |
| Prezcobix (darunavir/cobicistat) | 23 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Indianapolis, IN | 17 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $21.00 in total to this clinician.
| Biomerieux Inc | $21.00 |
|---|
| Food and Beverage | $21.00 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $36,690 in research payments for these studies, mostly to the institutions running them.
- Quicksilver
Becton, Dickinson and Company - COREntericsBB+
Becton, Dickinson and Company - SpotFire R Mini ANS Prospective Study
Biofire Diagnostics, LLC - SpotFire STI Prospective Study
Biofire Diagnostics, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.